RBC raises Johnson & Johnson stock target to USD 290.00

Published on 10/14/2026 at 15:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sales hit USD 25.40 billion in third quarter 2026. Johnson & Johnson stock costs EUR 224.68 on October 14, 2026, plus 1.14 percent versus Xetra close.

Analyst target and quarterly sales

RBC Capital raised its Johnson & Johnson target to USD 290.00 on October 11, 2026.
Sales rose 5.90 percent to USD 25.40 billion in the third quarter of 2026.
Johnson & Johnson stock costs EUR 224.68 at Lang & Schwarz on October 14, 2026 at 3:01 p.m. CEST, plus 1.14 percent versus the Xetra close of October 13, 2026.
Johnson & Johnson had a market capitalization of USD 599.1 billion as of October 13, 2026.

Extreme macro photograph of a single white pharmaceutical tablet on a pale grey surface, a fine score line running diagonally across its center in sharp focus, micro-granular chalky texture visible across the pill surface, soft diffuse highlights along th — Johnson Pharmapille im Makro, US4781601046 zeigt Bruchrille und feine Tablet Textur im Detail, Illustration mit AI erstellt.

RBC Capital raised its Johnson & Johnson target from USD 287.00 to USD 290.00, as Yahoo Finance reported on October 11, 2026. Against the USD 248.61 home-market price dated October 13, 2026, the target stood 16.65 percent higher. Johnson & Johnson stock was trading at EUR 224.68 at Lang & Schwarz on October 14, 2026 at 3:01 p.m. CEST, plus 1.14 percent versus the Xetra close of October 13, 2026 at EUR 222.15.

Third-quarter sales reach USD 25.40 billion

Johnson & Johnson reported third-quarter 2026 sales of USD 25.40 billion, up 5.90 percent from USD 23.99 billion in the third quarter of 2025, according to Johnson & Johnson on October 13, 2026. Adjusted diluted earnings per share came to USD 2.59, while reported diluted earnings per share was USD 0.09 after a one-time charge tied to proposed talc litigation resolution and acquisition-related items.

The company also raised its full-year 2026 adjusted earnings per share guidance to USD 11.05-11.15, with a midpoint of USD 11.10. Estimated reported sales guidance was USD 101.0-101.4 billion, placing the midpoint at USD 101.2 billion, according to the same October 13 release.

Stock stays below its yearly high

The Lang & Schwarz price of EUR 224.68 was 7.16 percent below the EUR 242.00 52-week high shown for the euro listing on October 14, 2026. The same quote listed a 52-week low of EUR 158.56, leaving the stock 41.72 percent above that level.

In the United States, Johnson & Johnson traded at USD 248.61 on October 13, 2026. The NYSE listing had a 52-week range of USD 184.66 to USD 281.07, a market capitalization of USD 599.1 billion and a price-to-earnings ratio of 37.69.

Valuation and peer figures

The dividend yield was 2.00 percent on the October 13, 2026 quote. Abbott Laboratories traded at USD 102.67 on October 13, 2026, up 0.83 percent, with a price-to-earnings ratio of 33.01 and market capitalization of USD 177.7 billion.

Pfizer traded at USD 28.37 on October 13, 2026, down 0.11 percent, with a price-to-earnings ratio of 37.49 and market capitalization of USD 161.7 billion. These peer figures place Johnson & Johnson above both comparison companies by market value, while its price-to-earnings ratio is higher than Abbott Laboratories and close to Pfizer.

Trading position and investor reference

The central tension is numerical: third-quarter sales increased 5.90 percent, but the reported earnings figure was reduced by a one-time charge. At the same time, the adjusted full-year earnings midpoint of USD 11.10 is above the prior midpoint of USD 11.04 cited in the October 13 release.

The stock therefore combines a fresh analyst target of USD 290.00 with an intraday euro price below its 52-week high. The next market assessment will depend on whether the higher adjusted outlook can outweigh the effect of special items on reported earnings.

The further course of trading is shown by the continuously updated real-time quote of Johnson & Johnson stock.